Joseph K. Han

This HCPLive Five captures 5 interviews conducted on-site at AAAAI 2026.

Han discusses late-breaking phase 2 VIBRANT data at AAAAI 2026, which showed that quarterly TSLP receptor blockade reduced the need for CRSwNP by 76%.

At AAAAI 2026, Han reports pooled ANCHOR data showing depemokimab improved nasal symptoms, QoL, and cut rescue interventions.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key allergy updates from the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting.

Tezepelumab significantly reduced nasal polyp severity in CRSwNP patients during the phase 3 WAYPOINT trial, lowering the need for surgery by 92%.